267 related articles for article (PubMed ID: 28285341)
1. Improved quality of risk-reducing salpingo-oophorectomy in Australasian women at high risk of pelvic serous cancer.
Lee YC; Bressel M; Grant P; Russell P; Smith C; Picken S; Camm S; Kiely BE; Milne RL; McLachlan SA; Hickey M; Friedlander ML; Hopper JL; Phillips KA;
Fam Cancer; 2017 Oct; 16(4):461-469. PubMed ID: 28285341
[TBL] [Abstract][Full Text] [Related]
2. The Role of Routine Peritoneal and Omental Biopsies at Risk-Reducing Salpingo-Oophorectomy.
Miller H; Pipkin LS; Tung C; Hall TR; Masand RP; Anderson ML
J Minim Invasive Gynecol; 2017; 24(5):772-776. PubMed ID: 28285055
[TBL] [Abstract][Full Text] [Related]
3. Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancer.
Kiely BE; Friedlander ML; Milne RL; Stanhope L; Russell P; Jenkins MA; Weideman P; McLachlan SA; Grant P; ; Hopper JL; Phillips KA
Fam Cancer; 2011 Sep; 10(3):505-14. PubMed ID: 21424757
[TBL] [Abstract][Full Text] [Related]
4. The prevalence of occult ovarian cancer in the series of 155 consequently operated high risk asymptomatic patients - Slovenian population based study.
Gornjec A; Merlo S; Novakovic S; Stegel V; Gazic B; Perhavec A; Blatnik A; Krajc M
Radiol Oncol; 2020 May; 54(2):180-186. PubMed ID: 32463390
[TBL] [Abstract][Full Text] [Related]
5. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J
Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744
[TBL] [Abstract][Full Text] [Related]
6. Pathological findings following risk-reducing salpingo-oophorectomy in BRCA mutation carriers: A systematic review and meta-analysis.
Cheng A; Li L; Wu M; Lang J
Eur J Surg Oncol; 2020 Jan; 46(1):139-147. PubMed ID: 31521389
[TBL] [Abstract][Full Text] [Related]
7. Retrospective study of a 16 year cohort of BRCA1 and BRCA2 carriers presenting for RRSO: Prevalence of invasive and in-situ carcinoma, with follow-up.
Blok F; Dasgupta S; Dinjens WNM; Roes EM; van Beekhuizen HJ; Ewing-Graham PC
Gynecol Oncol; 2019 May; 153(2):326-334. PubMed ID: 30894273
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of risk-reducing salpingo-oophorectomy in patients with BRCA1/2 mutation.
Abay M; Ozgen L; Yalcin Y; Ozerkan K
J Gynecol Obstet Hum Reprod; 2023 Oct; 52(8):102642. PubMed ID: 37573025
[TBL] [Abstract][Full Text] [Related]
9. Primary fallopian tube carcinoma (PFTC) in a BRIP-1 mutation carrier: the first case report.
Grandi G; Caroli M; Alboni C; Cortesi L; Toss A; Barbieri E; Botticelli L; Facchinetti F
Fam Cancer; 2020 Oct; 19(4):291-295. PubMed ID: 32328861
[TBL] [Abstract][Full Text] [Related]
10. Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens.
Reitsma W; de Bock GH; Oosterwijk JC; Bart J; Hollema H; Mourits MJ
Eur J Cancer; 2013 Jan; 49(1):132-41. PubMed ID: 22921157
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of risk-reducing salpingo-oophorectomy in BRCA1-2 variants and clinical outcomes of follow-up in patients with isolated serous tubal intraepithelial carcinoma (STIC).
Saccardi C; Zovato S; Spagnol G; Bonaldo G; Marchetti M; Alessandrini L; Tognazzo S; Guerriero A; Vitagliano A; Laganà AS; Noventa M
Gynecol Oncol; 2021 Nov; 163(2):364-370. PubMed ID: 34465478
[TBL] [Abstract][Full Text] [Related]
12. Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199.
Sherman ME; Piedmonte M; Mai PL; Ioffe OB; Ronnett BM; Van Le L; Ivanov I; Bell MC; Blank SV; DiSilvestro P; Hamilton CA; Tewari KS; Wakeley K; Kauff ND; Yamada SD; Rodriguez G; Skates SJ; Alberts DS; Walker JL; Minasian L; Lu K; Greene MH
J Clin Oncol; 2014 Oct; 32(29):3275-83. PubMed ID: 25199754
[TBL] [Abstract][Full Text] [Related]
13. Mortality reduction and cost-effectiveness of performing hysterectomy at the time of risk-reducing salpingo-oophorectomy for prophylaxis against serous/serous-like uterine cancers in BRCA1 mutation carriers.
Havrilesky LJ; Moss HA; Chino J; Myers ER; Kauff ND
Gynecol Oncol; 2017 Jun; 145(3):549-554. PubMed ID: 28390820
[TBL] [Abstract][Full Text] [Related]
14. Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience.
Rush SK; Swisher EM; Garcia RL; Pennington KP; Agnew KJ; Kilgore MR; Norquist BM
Gynecol Oncol; 2020 May; 157(2):514-520. PubMed ID: 32199636
[TBL] [Abstract][Full Text] [Related]
15. Development of Peritoneal Carcinoma in women diagnosed with Serous Tubal Intraepithelial Carcinoma (STIC) following Risk-Reducing Salpingo-Oophorectomy (RRSO).
Stanciu PI; Ind TEJ; Barton DPJ; Butler JB; Vroobel KM; Attygalle AD; Nobbenhuis MAE
J Ovarian Res; 2019 May; 12(1):50. PubMed ID: 31128592
[TBL] [Abstract][Full Text] [Related]
16. Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers.
Lee YJ; Lee SW; Kim KR; Jung KH; Lee JW; Kim YM
J Gynecol Oncol; 2017 Jan; 28(1):e3. PubMed ID: 27670257
[TBL] [Abstract][Full Text] [Related]
17. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.
Manchanda R; Abdelraheim A; Johnson M; Rosenthal AN; Benjamin E; Brunell C; Burnell M; Side L; Gessler S; Saridogan E; Oram D; Jacobs I; Menon U
BJOG; 2011 Jun; 118(7):814-24. PubMed ID: 21392246
[TBL] [Abstract][Full Text] [Related]
18. Clinical and pathological outcomes of risk-reducing salpingo-oophorectomy for Japanese women with hereditary breast and ovarian cancer.
Nomura H; Ikki A; Fusegi A; Omi M; Aoki Y; Netsu S; Tanigawa T; Matoda M; Okamoto S; Omatsu K; Nakajima T; Ueki A; Tonooka A; Kanao H
Int J Clin Oncol; 2021 Dec; 26(12):2331-2337. PubMed ID: 34453642
[TBL] [Abstract][Full Text] [Related]
19. Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol.
Powell CB; Chen LM; McLennan J; Crawford B; Zaloudek C; Rabban JT; Moore DH; Ziegler J
Int J Gynecol Cancer; 2011 Jul; 21(5):846-51. PubMed ID: 21670699
[TBL] [Abstract][Full Text] [Related]
20. Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis.
Yates MS; Meyer LA; Deavers MT; Daniels MS; Keeler ER; Mok SC; Gershenson DM; Lu KH
Cancer Prev Res (Phila); 2011 Mar; 4(3):463-70. PubMed ID: 21278312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
